Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
143.94
-4.36 (-2.94%)
At close: Mar 28, 2025, 4:00 PM
142.38
-1.56 (-1.09%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Natera Revenue
In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth. Natera had revenue of $476.06M in the quarter ending December 31, 2024, with 53.02% growth.
Revenue (ttm)
$1.70B
Revenue Growth
+56.75%
P/S Ratio
10.58
Revenue / Employee
$382,704
Employees
4,434
Market Cap
19.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
NTRA News
- 4 days ago - DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting - Business Wire
- 12 days ago - Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time - Seeking Alpha
- 19 days ago - Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer - Business Wire
- 25 days ago - Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD - Business Wire
- 4 weeks ago - Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Natera Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 4 weeks ago - Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer - Business Wire
- 5 weeks ago - Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025 - Business Wire